Neuland Laboratories Ltd's Q3FY25 Quarter Results
- 11 Feb 2025
Result Summary
- Neuland Laboratories Ltd reported a 27.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 1.8%.
- Its expenses for the quarter were up by 24.2% QoQ and 13.6% YoY.
- The net profit increased 209.3% QoQ and increased 24.8% YoY.
- The earnings per share (EPS) of Neuland Laboratories Ltd stood at 79.2 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 401.94 | 315.18 | 394.93 | 27.5% | 1.8% |
Total Expenses | 329.95 | 265.75 | 290.44 | 24.2% | 13.6% |
Profit Before Tax | 127.76 | 49.42 | 104.48 | 158.5% | 22.3% |
Tax | 26.18 | 16.58 | 23.09 | 57.9% | 13.4% |
Profit After Tax | 101.59 | 32.84 | 81.39 | 209.3% | 24.8% |
Earnings Per Share | 79.20 | 25.60 | 63.40 | 209.4% | 24.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Neuland Laboratories Ltd is a company primarily engaged in the pharmaceutical industry, specializing in the manufacturing of active pharmaceutical ingredients (APIs). The company operates in a sector known for its rigorous regulatory environment and significant demand for innovation and quality. Neuland Laboratories serves both domestic and international markets, supplying APIs to generic and branded pharmaceutical companies globally. In recent years, the company has focused on expanding its product portfolio and enhancing its manufacturing capabilities to meet the growing demands of the pharmaceutical industry. However, details on any recent major developments specific to this quarter are not available within the provided data.
Revenue
For the third quarter of fiscal year 2025 (Q3FY25), Neuland Laboratories Ltd reported a total income of ₹401.94 crores, marking a 27.5% increase from the previous quarter (Q2FY25) and a 1.8% increase year-over-year (YoY) compared to the same quarter in the previous year (Q3FY24). The quarter-over-quarter (QoQ) growth indicates an increase in revenue generation, reflecting on the company's ability to boost its income over the previous quarter. The YoY growth, although modest, suggests a steady performance compared to the corresponding period last year. The revenue trends suggest a positive trajectory in the company's financial performance over the recent quarters.
Profitability
In Q3FY25, Neuland Laboratories Ltd achieved a profit before tax of ₹127.76 crores, which is a significant improvement from ₹49.42 crores in Q2FY25. This represents a 158.5% QoQ increase. On a YoY basis, there was a 22.3% increase from ₹104.48 crores in Q3FY24. The company also recorded a profit after tax of ₹101.59 crores, which is a 209.3% increase QoQ and a 24.8% increase YoY. This sharp rise in profitability metrics suggests effective cost management or increased revenue streams. The earnings per share (EPS) stood at ₹79.20 in Q3FY25, compared to ₹25.60 in Q2FY25 and ₹63.40 in Q3FY24, reflecting similar trends in profitability metrics.
Operating Metrics
The total expenses for Neuland Laboratories Ltd in Q3FY25 amounted to ₹329.95 crores, showing a 24.2% increase from Q2FY25's ₹265.75 crores and a 13.6% increase YoY from ₹290.44 crores in Q3FY24. This increase in expenses suggests operational scaling or increased investment in production capacity. The tax expense for the quarter was ₹26.18 crores, increasing 57.9% QoQ from ₹16.58 crores and 13.4% YoY from ₹23.09 crores. This increase in tax aligns with the rise in profitability, indicating higher taxable income. The financial data reflects the company's operational changes over the quarters, while maintaining a focus on enhancing its financial health and performance.
